Dublin, Ireland, October 30, 2019 – Inflection Biosciences Ltd today announced that John Scanlan, a co-founder and a member of its Board of Directors, passed away Wednesday, October 23, 2019.
“John was instrumental in the establishment of Inflection Biosciences in 2012 and was a valued member of the Board ever since, providing important insight and guidance. A dear friend and colleague, we are very saddened by the news of his passing and he will be dearly missed. On behalf of the entire team at Inflection Biosciences we extend our deepest sympathies and condolences to John’s family,” stated Darren Cunningham, the company’s Chief Executive Officer.
A co-founder and a member of Inflection Biosciences Board since inception in 2012, John Scanlan also served as Director of Commercialisation at Maynooth University, an office he set up in 2005. He led the Technology Transfer alliance of Maynooth University, Athlone Institute of Technology (AIT), Institute of Technology Carlow (ITC) and Waterford Institute of Technology (WIT). Previously, he was CTO of Straatum, a software and hardware supplier to the semiconductor industry spun out from his PhD thesis and acquired by Lam Research in California.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class AUM300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com